Drug
Abobotulinum toxin A
Abobotulinum toxin A is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(25%)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_4
2
50%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 4Post-market surveillance
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Other(3)
Detailed Status
unknown3
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 42 (66.7%)
N/A1 (33.3%)
Trials by Status
unknown375%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
unknown
Valuation of the Evolution of Passive Mobility in the Spastic Upper Limb After Injection of Abobotulinumtoxin(Dysport®)
NCT05151874
recruitingphase_4
A Cross Over Pilot Study of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor
NCT03136341
unknownphase_4
Frontalis Botulinum Toxin
NCT03186001
unknownnot_applicable
Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's Syndrome
NCT02187679
Clinical Trials (4)
Showing 4 of 4 trials
NCT05151874
Valuation of the Evolution of Passive Mobility in the Spastic Upper Limb After Injection of Abobotulinumtoxin(Dysport®)
NCT03136341Phase 4
A Cross Over Pilot Study of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor
NCT03186001Phase 4
Frontalis Botulinum Toxin
NCT02187679Not Applicable
Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's Syndrome
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4